Clinical Trials

Several clinical trials are currently evaluating protocols associated with this designation across a broad therapeutic spectrum, including Hodgkin's and non-Hodgkin's lymphomas, solid tumors, cardiovascular disorders, fibromyalgia, and atopic dermatitis. Ranging from Phase I to Phase IV alongside non-interventional designs, these actively recruiting studies are led by academic medical centers—including Baylor College of Medicine, University Hospital Basel, Erasme University Hospital, and the University of Michigan—as well as industry sponsors such as TScan Therapeutics and Innovaderm Research.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05134740 Recruiting
Hodgkins Lymphoma|Non Hodgkins Lymphoma
Baylor College of Medicine|Center for Cell and Gene Therapy Baylor College of Medicine
 2024-04 Phase 1
NCT06353607 Recruiting
Acute Aortic Dissection|Thoracic Aortic Aneurysm
University Hospital Basel Switzerland
 2024-04-08 --
NCT06286358 Recruiting
Aortic Valve Disease|Aortic Aneurysm
Université Libre de Bruxelles|Erasme University Hospital
 2024-03-07 --
NCT06208514 Recruiting
Fibromyalgia
University of Michigan
 2024-03-04 Not Applicable
NCT05812027 Recruiting
Head and Neck Cancer|Cervical Cancer|Non Small Cell Lung Cancer|Melanoma|Ovarian Cancer|HPV16 Related Cancers
TScan Therapeutics Inc.
 2023-06-26 --
NCT05844618 Recruiting
Atopic Dermatitis
Innovaderm Research Inc.
 2023-05-09 Phase 4

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Thioacetamide product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Thioacetamide undergoes metabolic bioactivation by microsomal enzymes to generate reactive thiono-dioxide intermediates that covalently bind to cellular proteins and lipids, causing oxidative stress and severe metabolic disruption. This intracellular damage leads to plasma membrane permeabilization and centrilobular necrosis, establishing a classic model of hepatic toxicity and cirrhosis that provides mechanistic insights into cellular injury processes observed across clinical conditions involving tissue inflammation and oncogenesis.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.